Empowered Patient Podcast

Bill Stilley is the CEO and President of Adial Pharmaceuticals, which is focused on developing medicinal therapies for the treatment and prevention of addiction. Their first drug is a genetically targeted drug to treat alcohol use disorder, otherwise known as alcoholism.

Bill explains, "Yes, in the end, a lot of diseases are based on our genetics, and addiction seems to have some genetic components. I mean, for decades, it's been known that people that have had family members with an alcohol use problem have a much higher rate, and the numbers thrown around a lot are a nine times greater likelihood to have the problem themselves. Of course, some of that's going to be due to an environment, but it's clear that there's a genetic component."

"So, we believe that we have identified some defects in the serotonin system of certain patients which will allow them to respond to treatment with our drug, which is a serotonin-3 receptor blocker. By that, I mean what it seems to indicate in clinical trials to date, is that we can reduce the craving that these patients have that's driven through their serotonin system to encourage them where they have a need to drink, rather than just a desire to drink."

"In our phase 2 study, which is a 283 patient clinical trial that was run with our drug, patients that were on the drug that had the right genetics reduced the frequency of their drinking by almost 50%. When they drank, they reduced the amount they drank by almost 60%. So they picked up the bottle less often, and when they picked it up, they could put it back down. We think this is a really meaningful result for these people."

@AdialPharma #Addiction #AlcoholUseDisorder #Alcoholism #AddictionTreatment #MentalHealth

adialpharma.com

Listen to the podcast here

Bill Stilley is the CEO and President of Adial Pharmaceuticals, which is focused on developing medicinal therapies for the treatment and prevention of addiction. Their first drug is a genetically targeted drug to treat alcohol use disorder, otherwise known as alcoholism.

Bill explains, "Yes, in the end, a lot of diseases are based on our genetics, and addiction seems to have some genetic components. I mean, for decades, it's been known that people that have had family members with an alcohol use problem have a much higher rate, and the numbers thrown around a lot are a nine times greater likelihood to have the problem themselves. Of course, some of that's going to be due to an environment, but it's clear that there's a genetic component."

"So, we believe that we have identified some defects in the serotonin system of certain patients which will allow them to respond to treatment with our drug, which is a serotonin-3 receptor blocker. By that, I mean what it seems to indicate in clinical trials to date, is that we can reduce the craving that these patients have that's driven through their serotonin system to encourage them where they have a need to drink, rather than just a desire to drink."

"In our phase 2 study, which is a 283 patient clinical trial that was run with our drug, patients that were on the drug that had the right genetics reduced the frequency of their drinking by almost 50%. When they drank, they reduced the amount they drank by almost 60%. So they picked up the bottle less often, and when they picked it up, they could put it back down. We think this is a really meaningful result for these people."

@AdialPharma #Addiction #AlcoholUseDisorder #Alcoholism #AddictionTreatment #MentalHealth

adialpharma.com

Download the transcript here

Dr. Mark Berman is the Chief Medical Officer at Better Therapeutics, using a prescription digital therapeutic to treat diseases caused by human behavior, particularly type II diabetes. While PDT model might be expected to be effective with younger patients, clinical trial data is revealing that older patients 60+ are getting the most benefit in blood sugar reduction from this approach.

Mark elaborates, "We are, at Better Therapeutics, trying to pioneer a prescription digital therapeutics platform with the intent of treating a whole host of cardiometabolic conditions, starting first with type II diabetes. Then moving on to other related cardiometabolic conditions that all share their roots in health behaviors that really drive the pandemic of disease that we're seeing in cardiometabolic health. And so, at Better Therapeutics, we're bringing about this platform to enable scalable means of treating those root causes of cardiometabolic conditions."

"The notion of prescription digital therapeutic is that instead of prescribing yet another drug to help those types of patients, they're going to prescribe an FDA regulated mobile medical app, a prescription digital therapeutic, which is easy to fill, and it comes directly onto the patient's smartphone. And from there, it's the job of the digital therapeutic to really personalize the therapy for the patient. We don't believe that the providers have the time or the ability to really get very granular into the nature of the behavioral therapy. We really need to rely on the digital therapeutic to do that personalized work about what behaviors to target and how to be effective in each patient."

@Better_TX #DigitalTherapeutics #DigitalHealth #PDT #PrescriptionDigitalTherapeutic #Type2Diabetes #MobileHealth

BetterTX.com

Listen to the podcast here

Dr. Mark Berman is the Chief Medical Officer at Better Therapeutics, using a prescription digital therapeutic to treat diseases caused by human behavior, particularly type II diabetes. While PDT model might be expected to be effective with younger patients, clinical trial data is revealing that older patients 60+ are getting the most benefit in blood sugar reduction from this approach.

Mark elaborates, "We are, at Better Therapeutics, trying to pioneer a prescription digital therapeutics platform with the intent of treating a whole host of cardiometabolic conditions, starting first with type II diabetes. Then moving on to other related cardiometabolic conditions that all share their roots in health behaviors that really drive the pandemic of disease that we're seeing in cardiometabolic health. And so, at Better Therapeutics, we're bringing about this platform to enable scalable means of treating those root causes of cardiometabolic conditions."

"The notion of prescription digital therapeutic is that instead of prescribing yet another drug to help those types of patients, they're going to prescribe an FDA regulated mobile medical app, a prescription digital therapeutic, which is easy to fill, and it comes directly onto the patient's smartphone. And from there, it's the job of the digital therapeutic to really personalize the therapy for the patient. We don't believe that the providers have the time or the ability to really get very granular into the nature of the behavioral therapy. We really need to rely on the digital therapeutic to do that personalized work about what behaviors to target and how to be effective in each patient."

@Better_TX #DigitalTherapeutics #DigitalHealth #PDT #PrescriptionDigitalTherapeutic #Type2Diabetes #MobileHealth

BetterTX.com

Download the transcript here

Dr. Tom Lendvay is the Chief Medical Officer of Tend, which addresses the gut microbiome of the severe intestinal infection Clostridium difficile CDIF. Currently, recurrent Clostridium difficile is the only FDA-regulated disease for the use of microbiome transplants outside of a clinical trial. Clinical trials are also underway applying microbiome transplants to intestinal diseases such as inflammatory bowel diseases, irritable bowel syndrome, and other diseases outside of the gut.

Tom explains, "Tend is focused on two types of offerings. One is a device called the CAP device, a collection processing device that allows a clinician or a researcher to collect a sample and process it, mix it, filter it and encapsulate it into orally ingestible capsules that can be stored in a freezer."

"The other side is the data side, which is understanding. So, doing microbiome analyses on the donors, on the recipient ill patients and seeing how their microbiome changes over time and learning who's the best donor for the best recipient. Those two offerings do not exist today, and right now, the process for a clinician, for a researcher to provide microbiome transplants to their patients is extremely onerous and laborious."

@Tend_Health #FMT #CDIF #Microbiome #GutMicrobiome #MedicalDevice #Healthcare #Patient

tend-health.com

Listen to the podcast here

Dr. Tom Lendvay is the Chief Medical Officer of Tend, which addresses the gut microbiome of the severe intestinal infection Clostridium difficile CDIF. Currently, recurrent Clostridium difficile is the only FDA-regulated disease for the use of microbiome transplants outside of a clinical trial. Clinical trials are also underway applying microbiome transplants to intestinal diseases such as inflammatory bowel diseases, irritable bowel syndrome, and even other diseases outside of the gut.

Tom explains, "Tend is focused on two types of offerings. One is a device called the CAP device, a collection processing device that allows a clinician or a researcher to collect a sample and process it, mix it, filter it and encapsulate it into orally ingestible capsules that can be stored in a freezer."

"The other side is the data side, which is understanding. So, doing microbiome analyses on the donors, on the recipient ill patients and seeing how their microbiome changes over time and learning who's the best donor for the best recipient. Those two offerings do not exist today, and right now, the process for a clinician, for a researcher to provide microbiome transplants to their patients is extremely onerous and laborious."

@Tend_Health #FMT #CDIF #Microbiome #GutMicrobiome #MedicalDevice #Healthcare #Patient

tend-health.com

Download the transcript here

Russ Thomas, the CEO of Availity, and Oron Afek, CEO and Co-Founder of Vim, join me in discussing the benefits of breaking down information silos of the payers and care providers and bringing real-time data to the point of care. By integrating actionable patient information at the right point of time, providers are better informed to improve patient outcomes.

Russ explains, "Availity, for the last 21 years now, has been in the business of developing connectivity and relationships between health plans and providers. I know we're going to talk a lot today about the really cool program we've embarked upon with Oron and the Vim team. But at our core, we sit in the center of the relationship between health plans and providers and communicate all types of health information between these critical constituents."

Oron elaborates, "One of the goals for the Availity-Vim partnership is to really drive behavioral change based on real-time decision-making. It is to intercept at the point of care, at the point of intent, intercept decision-making points that can influence things like downstream costs or administrative costs, like submitting prior authorization, or other components in the entire trajectory, and influence them. This is instead of doing some retrospect analysis for engagement that is usually more expensive, because when you don't catch a person at the point of intent, then you most often end up paying a lot more to engage them, in retrospect."

@Availity @GetVim #PointofCare #PriorAuthorization #Ai #ComputerVision

Availity.com

GetVim.com

Listen to the podcast here

Russ Thomas, the CEO of Availity, and Oron Afek, CEO and Co-Founder of Vim, join me in discussing the benefits of breaking down information silos of the payers and care providers and bringing real-time data to the point of care. By integrating actionable patient information at the right point of time, providers are better informed to improve patient outcomes.

Russ explains, "Availity, for the last 21 years now, has been in the business of developing connectivity and relationships between health plans and providers. I know we're going to talk a lot today about the really cool program we've embarked upon with Oron and the Vim team. But at our core, we sit in the center of the relationship between health plans and providers and communicate all types of health information between these critical constituents."

Oron elaborates, "One of the goals for the Availity-Vim partnership is to really drive behavioral change based on real-time decision-making. It is to intercept at the point of care, at the point of intent, intercept decision-making points that can influence things like downstream costs or administrative costs, like submitting prior authorization, or other components in the entire trajectory, and influence them. This is instead of doing some retrospect analysis for engagement that is usually more expensive, because when you don't catch a person at the point of intent, then you most often end up paying a lot more to engage them, in retrospect."

@Availity @GetVim #PointofCare #PriorAuthorization #AI #ComputerVision

Availity.com

GetVim.com

Download the transcript here

Avihai Sodri is the Co-Founder and CEO of Antidote Health, which takes a digital HMO approach to bring 24/7 healthcare to a broad audience. Their target patients include both insured people and those who are uninsured, anyone who requires a one-time service or care for a chronic condition.

Avihai says, "So, in a very significant sense, we're not reinventing the wheel. So we're talking about processes and best practices in providing healthcare in a very traditional way, I would say. But we're injecting a lot of technology with our decision support systems and the way that our bot collects information from the patient, and we are adding more digital processes more on the administrative side of things. So, if you take all this together, with the alignment of interest, then we can create a real disruption. And without changing dramatically, the way that healthcare is being provided, but the fact that we are using telehealth to provide the healthcare."

@AntidoteAI #AntidoteHealth #AI #DigitalHealth #Telemedicine #HMO #HealthcareProviders

antidotehealth.ai

Listen to the podcast here

Avihai Sodri is the Co-Founder and CEO of Antidote Health, which takes a digital HMO approach to bring 24/7 healthcare to a broad audience. Their target patients include both insured people and those who are uninsured, anyone who requires a one-time service or care for a chronic condition.

Avihai says, "So, in a very significant sense, we're not reinventing the wheel. So we're talking about processes and best practices in providing healthcare in a very traditional way, I would say. But we're injecting a lot of technology with our decision support systems and the way that our bot collects information from the patient, and we are adding more digital processes more on the administrative side of things. So, if you take all this together, with the alignment of interest, then we can create a real disruption. And without changing dramatically, the way that healthcare is being provided, but the fact that we are using telehealth to provide the healthcare."

@AntidoteAI #AntidoteHealth #AI #DigitalHealth #Telemedicine #HMO #HealthcareProviders

antidotehealth.ai

Download the transcript here